Trial Profile
A Prospective Multicentric Randomized Study of Glivec in Patients With Advanced Gastrointestinal Stromal Tumors Expressing c-Kit Comparing Treatment Interruption After 5 Years vs Treatment Maintenance
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 11 Dec 2015 Results of a subgroup analysis published in the European Journal of Cancer
- 21 Feb 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 25 Sep 2012 Planned End Date changed from 1 May 2017 to 1 May 2013 as reported by ClinicalTrials.gov.